ForumIAS announcing GS Foundation Program for UPSC CSE 2025-26 from 10th August. Click Here for more information.
Source– This post is based on the article “Breakthrough Nutraceutical ‘AKTOCYTE’ by the Department of Atomic Energy Set to Transform Cancer Care” published in “PIB” on 13th December 2023.
Why in the News?
AKTOCYTE tablets have been granted approval by the Food Safety and Standards Authority of India (FSSAI).
What are AKTOCYTE tablets?
| Specifications | Details |
| What is it? | Its a tablet used during cancer treatment to minimize the side effects of radiotherapy. |
| Developed by | Department of Atomic Energy and M/s. IDRS Labs Pvt. Ltd. Bengaluru |
| Characteristics | 1) Impressive Recovery in Pelvic Cancer: AKTOCYTE Tablets show promise in pelvic cancer patients suffering from radiotherapy-induced Cystitis (Blood in urine). 2) Versatile AKTOCYTE Tablets: Beyond a supplement, they serve as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant, highlighting their diverse applications in cancer care. 3) Safe: AKTOCYTE has received approval from the FSSAI. |
| Market Entry | AKTOCYTE Tablets, set to debut in January 2024, promise to revolutionize cancer treatment protocols. |
What is FSSAI?
1) Food Safety and Standards Authority of India (FSSAI) is a statutory body established under the Food Safety and Standards Act, 2006 (FSS Act).
2) FSSAI is an autonomous body under the Ministry of Health & Family Welfare.
| For more information on FSSAI Click Here to Read |
UPSC Syllabus- Science & Technology
